Faricimab for Wet Age-Related Macular Degeneration
How Faricimab Treats Wet AMD
Wet age-related macular degeneration (AMD) occurs when abnormal blood vessels grow beneath your macula, the part of your retina responsible for sharp central vision. These fragile vessels leak fluid and blood into the retinal layers, causing swelling that damages the cells you need for reading, driving, and recognizing faces. Without treatment, wet AMD can cause permanent central vision loss within weeks or months.
The abnormal vessel growth is driven by proteins your body produces in response to retinal stress. Blocking these proteins is the foundation of modern wet AMD treatment, and faricimab targets two of them at once.
Faricimab is the first bispecific antibody approved for eye conditions. According to the FDA (2022), it targets two proteins at once: VEGF-A (vascular endothelial growth factor A), which drives abnormal blood vessel growth, and angiopoietin-2 (Ang-2), which destabilizes blood vessel walls and increases leaking. By blocking both proteins, faricimab reduces swelling through two pathways instead of one.
The FDA approved faricimab on January 28, 2022, for wet AMD and diabetic macular edema. Other anti-VEGF medications target one protein. Faricimab's dual-action mechanism allows longer intervals between injections for many patients because it addresses both the growth of abnormal vessels and the instability that causes them to leak.
In the TENAYA and LUCERNE phase 3 trials, which enrolled 1,329 patients, faricimab matched the visual acuity gains of aflibercept given every two months. According to the FDA (2022), about 50 percent of patients achieved four-month dosing intervals within the first year. According to the AAO (2024), two-year real-world data showed about 80 percent of patients maintained at least three-month intervals and 60 percent reached four-month intervals.
These results mean that more than half of faricimab patients visited their retina specialist fewer times per year than they would on older treatment regimens, while achieving the same vision protection.
Your retina specialist may recommend faricimab if you have wet AMD and could benefit from fewer injection visits. According to the AAO (2022), patients with mobility or transportation challenges may find the extended dosing schedule easier to manage. Faricimab is also an option for patients starting treatment for the first time, those whose doctor recommends a switch from another anti-VEGF medication, or patients who have difficulty maintaining frequent visit schedules.
What Treatment Involves
Your retina specialist injects faricimab into the vitreous cavity of your eye through the white part of the eye using a small-gauge needle. Before the injection, your doctor applies numbing drops and antiseptic to your eye. A lid holder keeps your eye open during the injection, which takes only seconds. Most patients feel pressure but not sharp pain. Your vision may be blurry for several hours afterward, so bring a driver to the appointment.
According to FDA prescribing information (2024), treatment starts with 6 mg intravitreal injections monthly for the first four doses. This loading phase builds up medication in your eye and brings the leaking under control. Your retina specialist then evaluates your retina at weeks 8 and 12 to determine your extension interval. Depending on how your eye responds, you may receive injections every 8, 12, or 16 weeks after the loading phase.
According to the AAO (2024), most patients use treat-and-extend protocols once the loading doses are complete. Your doctor extends the interval step by step as long as your retina stays dry and shortens it if fluid returns.
At each visit, your retina specialist checks your vision and performs OCT (optical coherence tomography) imaging to look for fluid beneath or within your retina. These images guide dosing decisions and show whether the treatment is controlling the leaking vessels.
- Dry retina on OCT: your doctor may extend the interval between injections
- Fluid present on OCT: your doctor shortens the interval to regain control
- New vessel growth: your doctor may adjust the treatment plan
- Stable imaging over multiple visits: confirms the current schedule is working
Wet AMD is a chronic condition, and faricimab treatment is ongoing. The abnormal blood vessels can reactivate if you stop anti-VEGF medication, leading to new leaking, swelling, and vision loss. Your retina specialist will work toward the longest safe interval between injections while keeping your retina stable. Some patients maintain good control with just three or four injections per year after the loading phase.
Safety and Side Effects
The most common side effects after faricimab injections include mild eye discomfort, temporary blurred vision, small bleeds on the white of the eye (subconjunctival hemorrhage), and floaters. These resolve within a few days without treatment. A temporary rise in eye pressure can occur right after injection, which your doctor monitors before you leave the office.
Endophthalmitis (infection inside the eye) and retinal detachment are rare but serious complications of any intravitreal injection, occurring in fewer than 1 in 1,000 injections. Some patients have reported inflammation inside the eye with anti-VEGF treatments. Your retina specialist uses sterile technique and antiseptic preparation to minimize these risks. The risk does not increase with the number of injections you receive.
Call your retina specialist or seek emergency eye care if you experience any of the following in the days after an injection:
- Increasing eye pain that does not improve with time
- Sudden loss of vision or new dark spots
- A large increase in floaters or flashes of light
- Sensitivity to light or worsening redness
These may be signs of infection or retinal detachment that require same-day treatment to protect your vision.
Questions About Faricimab for Wet AMD
Faricimab blocks two proteins (VEGF-A and Ang-2) instead of one. This dual mechanism can produce longer-lasting fluid control, which is why many patients extend to three- or four-month dosing intervals. Other anti-VEGF drugs target VEGF-A alone or VEGF-A plus placental growth factor, offering fewer patients the same extended dosing benefit.
Your retina specialist can switch you from another anti-VEGF medication to faricimab. Doctors make this change when a patient needs less frequent dosing or when fluid control could improve with a different mechanism. Your doctor will evaluate your imaging and treatment history before recommending a switch and will monitor you during the transition.
The number depends on how your retina responds. During the loading phase, you receive four monthly injections. After that, patients who reach four-month intervals need about three additional injections per year. Patients on shorter intervals may need six to eight injections per year. Your doctor adjusts the schedule based on your OCT results at each visit.
Not all patients achieve four-month intervals. Your retina specialist extends your interval step by step and monitors your retina at each visit. Some patients do best with two- or three-month intervals. The goal is to find the longest safe interval that keeps your retina dry and your vision stable while minimizing your total number of office visits.
Your retina specialist may treat both eyes with faricimab if both have wet AMD. Each eye receives its own injection, sometimes on the same day and sometimes at separate visits depending on your doctor's approach and your comfort level. Treating both eyes on the same day reduces total office visits.
If you notice new distortion, blurriness, or dark spots between scheduled visits, contact your retina specialist right away. Your doctor may perform imaging sooner than planned and shorten your injection interval to regain control. Catching fluid recurrence early prevents additional retinal damage and preserves your visual gains.
Take Action for Your Vision
If you have wet AMD, ask your retina specialist whether faricimab could reduce your injection frequency while maintaining the visual gains you need. Consistent treatment and regular monitoring give you the best chance of preserving your central vision for the long term.